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Background
Monoclonal antibody (mAb) therapy has revolutionized
the treatment of a vast range of diseases, mostly in the
areas of oncology and autoimmune/inflammatory disor-
ders [1]. With a world market exceeding 60 billion USD
per year and six mAb related products in the top 10
selling drugs, the industry continues to grow at a fast
rate [2]. Chinese hamster ovary (CHO) cells are the pre-
ferred production host for therapeutic production of
mAbs due to their efficiency in performing post-transla-
tional modifications and their ability to produce proteins
with similar properties to native human proteins [3].
Surprisingly, despite products varying only by a few
amino acids in the variable region of a MAb, each pro-
duction cell line is still developed by generating and
screening a large strain pool, and generally the produc-
tion process has to be reoptimised.
Systems biology can be used as a powerful tool for
the identification of key markers of good production
lines, with the aim of engineering superior host lines
that more reliably produce good production clones. To
date systems biology efforts have been hampered by
the need to use the mouse, rat and/or human genome
as a reference and has suffered from the inherent lim-
itation in coverage of 2-dimensional gel electrophoresis
or mouse or CHO cDNA microarrays. The develop-
ment of new techniques such as RNA sequencing for
transcriptome analysis and LC-MS/MS for proteome
analysis combined with the recent release of the CHO
genome has reignited interest in using quantitative
proteomics and transcriptomics to study high produc-
tivity cell lines.
Materials and methods
Here we applied the latest generation of tools to two CHO
cell lines that produce different levels of mAb, as described
in Orellana et al [4]. The two cell lines were derived from
one transfection pool using the same plasmid carrying
genes for a monoclonal antibody. For each cell line, three
independent vials were thawed and passaged for two
weeks prior to bioreactor inoculation. Cells were cultivated
in 700 ml EX-CELL® CD CHO Fusion Medium (Sigma
Aldrich) containing 25 µM L-Methionine sulfoximine as
selection, in a 1L Mini-Bioreactor (Applikon Biotechnolo-
gies) operated at 125 rpm stirring speed, 37°C, pH 6.9 and
dissolved oxygen at 50% air saturation.
RNA and protein were extracted from cells harvested
in mid exponential phase. RNA samples were analysed
with RNA sequencing (RNA-Seq) using the Illumina
Hiseq2000 platform and 100 bp paired-end reads.
TopHat and Cufflinks open-source software [5] were
used with default settings for gene expression analysis,
using the CHO genome as reference. Protein samples
were analysed using SWATH [6]. The Paragon Algorithm
from ProteinPilot v4.5 (ABSciex, Forster City CA) [7],
PeakView v.1.2 software (ABSciex, Forster City CA) and
the R package Limma [8] were used for data analysis.
Transcripts and proteins were classified as differentially
expressed if the adjusted p-value (Benjamini-Hochberg)
was lower than 0.05.Gene set enrichment analysis was
performed using DAVID Bioinformatics functional
annotation tool [9].
Results and discussion
The high producer cell line displayed a slightly slower
growth rate of 0.0310 ± 0.0002 h-1 compared to the low
producer cell line with 0.0340 ± 0.0004 h-1. The two cell
lines achieved a titre of 104.3 ± 5.5 mg/L and 52.9 ± 2.0
mg/L on day 4 respectively, with a four-fold difference in* Correspondence: lars.nielsen@uq.edu.au
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mAb specific productivity (19.5 ± 1.0 pg/cell/day compared
to 4.6 ± 0.2 pg/cell/day).
More than 100 million reads were obtained for each
sample by RNA-Seq, with more than 83% of the reads
mapping to the CHO reference genome.14,300 transcripts
and 714proteins were quantified and tested for differential
expression. Despite the fact that both clones come from
the same transfection pool, 58% of the quantified tran-
scripts and 56% of the quantified proteins varied signifi-
cantly. Figure 1 shows the log2-transformed fold change
between the high producer and the low producer cell lines
for common transcripts/proteins between RNA-Seq and
SWATH techniques. For most of the genes (80%), the
direction of regulation, i.e. up- or down-, agreed between
transcripts and proteins.
Three key biological processes were identified by pro-
teomics as up-regulated in the high producer cell line:
glutathione biosynthesis, actin filament processes and
intracellular transport, while several growth-related pro-
cesses were down-regulated as expected from the lower
growth rate. Metabolomic analysis confirmed that the
high producing cell line displayed higher intracellular
levels of glutathione. These processes may be important
for conferring high mAb production, and as such gene
candidates have been nominated for targeted engineering
of high-expression cell lines.
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